Immune Systems Advisor

Key Takeaways The first published real-world study of pre-prescribed emergency medication kits analyzed responses from 506 verified purchasers. Nearly 72% of respondents used their kit at least once. More than 81% reported meaningful improvement within three days. Only 2.4% reported side effects, all classified as mild. Over 86% reported no need for clinic, urgent care, or hospital visits after kit use. Preparedness and peace-of-mind benefits were reported even among individuals who never used the medications. Introduction Access to timely medical care has become increasingly challenging across many healthcare systems. Long wait times, physician shortages, pharmacy closures, travel-related barriers, and rising healthcare costs often delay treatment for common acute illnesses. A 2026 released study titled Real-World Utilization, Outcomes, and Safety of Pre-Prescribed Emergency Medication Kits provides the first published real-world evidence evaluating how households actu...

More than four years after COVID-19 first appeared, many people still suffer from long-lasting symptoms after getting infected. This ongoing condition was often called 'Long COVID'. It means symptoms stick around for three months or more after the infection or after exposure to certain COVID-19 vaccines that use mRNA technology. In late 2023, some researchers introduced a new name, "SPIKEOPATHY," to explain that a protein called the Spike protein—found in both the virus and mRNA vaccines—plays a big role in causing these long-term problems. Because of this, the term Post-Spike Syndrome (PSS) is suggested as a clearer name for this condition. What is Post-Spike Syndrome? PSS can affect many parts of the body and cause serious, long-lasting health problems. Scientists are learning more about how the Spike protein causes these issues. The tiny particles from mRNA vaccines can travel through the body, not just stay where the shot was given. Both these particles and the Sp...

Immune Systems Advisor · Integrative Medicine White Paper · Open Access Authors: OneDayMD Editorial Team (synthesis and editorial adaptation) · Original protocols: Marik P, Kory P (IMA/FLCCC, 2022–2024); McCullough PA (Cureus, 2023) · Published: March 2023 · Last updated: June 2026 · DOI: n/a (educational synthesis) Evidence Tier Key:   TIER 1 RCT / systematic review   TIER 2 Observational / cohort   TIER 3 In vitro / mechanistic   TIER 4 Expert consensus / clinical observation ⚠ Medical Disclaimer — Please Read First. This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The protocols described involve supplements with significant anticoagulant activity. Always consult a licensed physician before starting, especially if you take blood thinners, are pregnant or breastfeeding, have a bleeding disorder, or...